Raras
Buscar doenças, sintomas, genes...
Paraplegia espástica autossômica recessiva tipo 62
ORPHA:401785CID-10 · G11.4CID-11 · 8B44.01OMIM 615681DOENÇA RARA

A Paraplegia Espástica Autossômica Recessiva Tipo 62 é uma doença genética hereditária (transmitida pelos pais) que causa fraqueza e rigidez muscular. Ela pode se apresentar de forma "pura" (apenas com os sintomas principais) ou "complexa" (com sintomas adicionais). Os sintomas costumam surgir na primeira década de vida, ou seja, antes dos 10 anos de idade. Caracteriza-se por fraqueza e rigidez nos músculos das pernas (mais evidente que nos braços) e dificuldade para andar de forma estável. Além disso, pode haver reflexos musculares muito fortes, perda de massa muscular (amiotrofia), dificuldade de coordenação motora (ataxia cerebelar) e, em alguns casos, os joelhos podem ficar permanentemente dobrados devido à rigidez (contraturas em flexão).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Paraplegia Espástica Autossômica Recessiva Tipo 62 é uma doença genética hereditária (transmitida pelos pais) que causa fraqueza e rigidez muscular. Ela pode se apresentar de forma "pura" (apenas com os sintomas principais) ou "complexa" (com sintomas adicionais). Os sintomas costumam surgir na primeira década de vida, ou seja, antes dos 10 anos de idade. Caracteriza-se por fraqueza e rigidez nos músculos das pernas (mais evidente que nos braços) e dificuldade para andar de forma estável. Além disso, pode haver reflexos musculares muito fortes, perda de massa muscular (amiotrofia), dificuldade de coordenação motora (ataxia cerebelar) e, em alguns casos, os joelhos podem ficar permanentemente dobrados devido à rigidez (contraturas em flexão).

Publicações científicas
363 artigos
Último publicado: 2026 Apr 1

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
7
pacientes catalogados
Início
Childhood
+ infancy
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G11.4
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
5 sintomas
🧠
Neurológico
5 sintomas
💪
Músculos
2 sintomas

+ 12 sintomas em outras categorias

Características mais comuns

100%prev.
Distúrbio da marcha
Frequente (79-30%)
100%prev.
Atrofia do músculo esquelético
Ocasional (29-5%)
100%prev.
Espasticidade do membro inferior
Muito frequente (99-80%)
100%prev.
Hiperreflexia
Frequente (79-30%)
100%prev.
Morfologia anormal do cerebelo
Ocasional (29-5%)
100%prev.
Espasticidade
Frequência: 7/7
24sintomas
Muito frequente (9)
Frequente (2)
Ocasional (9)
Muito raro (2)
Sem dados (2)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 24 características clínicas mais associadas, ordenadas por frequência.

Distúrbio da marchaGait disturbance
Frequente (79-30%)100%
Atrofia do músculo esqueléticoSkeletal muscle atrophy
Ocasional (29-5%)100%
Espasticidade do membro inferiorLower limb spasticity
Muito frequente (99-80%)100%
HiperreflexiaHyperreflexia
Frequente (79-30%)100%
Morfologia anormal do cerebeloAbnormal cerebellum morphology
Ocasional (29-5%)100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico363PubMed
Últimos 10 anos16publicações
Pico20204 papers
Linha do tempo
2026Hoje · 2026📈 2020Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

ERLIN1Erlin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the ERLIN1/ERLIN2 complex which mediates the endoplasmic reticulum-associated degradation (ERAD) of inositol 1,4,5-trisphosphate receptors (IP3Rs). Involved in regulation of cellular cholesterol homeostasis by regulation the SREBP signaling pathway (PubMed:37683630). Binds cholesterol and may promote ER retention of the SCAP-SREBF complex (PubMed:24217618) (Microbial infection) Required early in hepatitis C virus (HCV) infection to initiate RNA replication, and later in the infectio

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (3)
AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)ABC-family proteins mediated transportDefective CFTR causes cystic fibrosis
MECANISMO DE DOENÇA

Spastic paraplegia 62, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
58.3 TPM
Vagina
30.3 TPM
Fígado
28.9 TPM
Esôfago - Mucosa
25.4 TPM
Cervix Endocervix
24.5 TPM
OUTRAS DOENÇAS (1)
hereditary spastic paraplegia 62
HGNC:16947UniProt:O75477

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 Penicillamine (PENICILLAMINE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

24 variantes patogênicas registradas no ClinVar.

🧬 ERLIN1: NM_006459.4(ERLIN1):c.273del (p.Ile91fs) ()
🧬 ERLIN1: NM_006459.4(ERLIN1):c.176C>G (p.Thr59Ser) ()
🧬 ERLIN1: NM_006459.4(ERLIN1):c.305-7C>G ()
🧬 ERLIN1: GRCh37/hg19 10q23.1-25.1(chr10:87456174-107789979)x3 ()
🧬 ERLIN1: GRCh37/hg19 10q23.2-24.31(chr10:88755921-102461203)x1 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1,247 variantes classificadas pelo ClinVar.

125
1122
Patogênica (10.0%)
Benigna (90.0%)
VARIANTES MAIS SIGNIFICATIVAS
ATP13A2: NM_022089.4(ATP13A2):c.2436C>G (p.Tyr812Ter) [Likely pathogenic]
ATP13A2: NM_022089.4(ATP13A2):c.2592C>A (p.Cys864Ter) [Pathogenic]
ZFR: NM_016107.5(ZFR):c.3018G>A (p.Gln1006=) [Likely benign]
ATP13A2: NM_022089.4(ATP13A2):c.249C>T (p.Ala83=) [Likely benign]
ATP13A2: NM_022089.4(ATP13A2):c.2727C>T (p.Ser909=) [Likely benign]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Paraplegia espástica autossômica recessiva tipo 62

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
44 papers (10 anos)
#1

Expanding the Phenotypic Spectrum of ERLIN1-Related SPG62: Report of Two Siblings With Behavioral Features and Hyperacusis.

Clinical genetics2026 Jan

Hereditary spastic paraplegia type 62 (SPG62) is a neurodegenerative disorder, with more than 20 individuals reported to date. This ultra-rare entity is inherited in an autosomal recessive manner and has been associated with ERLIN1 variants. In addition, ERLIN1-related biallelic variants have been linked to early-onset amyotrophic lateral sclerosis (ALS). We present two siblings with slowly progressive spastic paraplegia, with mild intellectual decline, behavioral findings, and hyperacusis. This study expands the clinical spectrum of hereditary spastic paraplegia associated with ERLIN1.

#2

ERLIN1: A central regulator of protein quality control, lipid homeostasis, and cellular signaling at the endoplasmic reticulum.

Cellular signalling2026 Feb

Endoplasmic reticulum lipid raft-associated protein 1 (ERLIN1) is an endoplasmic reticulum (ER)-resident stomatin/prohibitin/flotillin/HflK/C (SPFH) family protein that assembles into oligomeric complexes within detergent-resistant membrane domains. ERLIN1 regulates multiple cellular functions, including protein quality control, calcium signaling, and lipid metabolism. Together with ERLIN2, it forms ER-associated degradation (ERAD) nanodomains through interactions with RING finger protein 170 (RNF170) and transmembrane and ubiquitin-like domain-containing 1 (TMUB1). These specialized domains facilitate the degradation of inositol 1,4,5-trisphosphate receptor type 1 (IP3R) via the ERAD pathway. ERLIN1 also controls cholesterol metabolism by inhibiting sterol regulatory element-binding protein (SREBP) activation and promoting 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) degradation. In addition, it blocks cholesterol esterification, thereby enhancing cholesterol transport to the Golgi apparatus. ERLIN1 further regulates cell fate by promoting autophagy and suppressing apoptosis; in complex with ERLIN2, it interacts with activating molecule in Beclin 1-regulated autophagy protein 1 (AMBRA1) at mitochondria-associated membranes to initiate autophagy and binds phosphatidylinositol 3-phosphate to stabilize autophagy signaling. Its overexpression enhances tumor progression, whereas silencing triggers apoptosis in colorectal cancer. Mutations in ERLIN1 are linked to neurodegenerative diseases such as hereditary spastic paraplegia type 62 and atypical amyotrophic lateral sclerosis. The ERLIN1/2 complex also influences immune responses and viral replication through cholesterol regulation. Collectively, these diverse and integrated functions highlight the potential of ERLIN1 as a therapeutic target in cancer, metabolic, neurodegenerative, and infectious diseases.

#3

Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A>C: A Case Report.

The American journal of case reports2026 Jan 07

BACKGROUND The most frequently mutated gene in hereditary spastic paraplegia (HSP) is SPAST. Only symptomatic treatment is available for this disease. Fampridine has been successfully used to treat gait disturbances in some patients with HSP. A positive effect of fampridine has not been previously reported in HSP4 caused by the c.683-2A>C variant in the SPAST gene. CASE REPORT We report the case of a 63-year-old woman with hypogeusia and hyposmia for several years, pollakiuria, gait disturbances, reduced walking speed, occasional dysphagia, constipation and delayed defecation, occasional memory problems, right-sided hearing loss, and exercise-induced myalgia and muscle cramps. Genetic testing revealed the c.683-2A>C variant in SPAST. Her 69-year-old sister also had pollakiuria since her youth, and since the age of 50 had frequent stumbling, unsteadiness, spasticity, and positional vertigo. At age 62, our patient began taking fampridine (4-aminopyridine) and has since experienced significant relief. Fampridine led to an improvement in spasticity, gait disorders, and walking speed, as documented by the 6-meter walk test, spastic paraplegia rating scale, and multidimensional self-esteem scale. CONCLUSIONS This case shows that HSP4 can progress slowly over a period of 7 years and can present with typical phenotypic characteristics of the disease as it progresses. The rate of progression can vary among affected family members, and people with HSP4 can still work even in old age and do not necessarily need antispastic drugs. This case also provides preliminary evidence that fampridine may be a viable symptomatic treatment option for patients with HSP4, including those with the mutation c.683-2A>C. It justifies further prospective, controlled studies in a larger SPAST-HSP population.

#4

KIF1C-related disorders: spastic ataxia or hypomyelinating leukodystrophy? A paradigm of classification ambiguity.

Neurogenetics2025 Aug 12

A 40-year-old man with adult-onset spastic-ataxia and tremor showed a leukoencephalopathy with a hypomyelinating pattern on brain MRI. Whole-exome sequencing identified two novel likely pathogenic variants in KIF1C, a gene associated with spastic-ataxia type 2 (SPAX2). This case supports including KIF1C among the causes of adult-onset hypomyelinating leukodystrophies and highlights the diagnostic overlap between spastic-ataxia, hereditary spastic paraplegia, and hypomyelinating leukodystrophies, underscoring the limitations of current nomenclature.

#5

New variants and genotype-phenotype correlation in KIF5A mutation: the contribution of a large Italian cohort.

Journal of medical genetics2025 Sep 19

Variants in the Kinesin-family member 5A (KIF5A) gene are associated with a range of motor diseases, and a strong correlation between the protein domains (motor, stalk and tail) and the clinical phenotype has been proposed. However, several studies have reported exceptions contributing to a complex genotype-phenotype correlation in recent years. Further studies are needed to improve our knowledge about the prevalence of KIF5A variants and their genotype-phenotype correlation. 390 patients (220 hereditary spastic paraplegia, 80 Charcot-Marie-Tooth disease type 2 and 90 amyotrophic lateral sclerosis) have been selected for next-generation sequencing Clinical Exome. Five patients have been found to carry causative variants in the KIF5A gene. Of these, three are familiar cases, and two are sporadic. Segregation analysis was performed on the familiar probands. The five patients with pathogenic variants represent 4% of the studied population, and the clinical and genetic analysis of these five families allowed us to examine different scenarios.Some of these data support the hypothesis of a complex correlation between domains and disease. These data confirm the complex genotype-phenotype correlation, both in terms of clinical heterogeneity associated with a specific domain and variability within the members of the same family, but also suggest a strong genotype-phenotype correlation, both intrafamiliar and interfamiliar, produced by a few variants.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC28 artigos no totalmostrando 16

2026

Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A>C: A Case Report.

The American journal of case reports
2026

Expanding the Phenotypic Spectrum of ERLIN1-Related SPG62: Report of Two Siblings With Behavioral Features and Hyperacusis.

Clinical genetics
2026

ERLIN1: A central regulator of protein quality control, lipid homeostasis, and cellular signaling at the endoplasmic reticulum.

Cellular signalling
2025

KIF1C-related disorders: spastic ataxia or hypomyelinating leukodystrophy? A paradigm of classification ambiguity.

Neurogenetics
2025

New variants and genotype-phenotype correlation in KIF5A mutation: the contribution of a large Italian cohort.

Journal of medical genetics
2024

Digital Gait Outcomes for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): Discriminative, Convergent, and Ecological Validity in a Multicenter Study (PROSPAX).

Movement disorders : official journal of the Movement Disorder Society
2022

Discrimination between hereditary spastic paraplegia and cerebral palsy based on gait analysis data: A machine learning approach.

Gait &amp; posture
2022

Genetic, structural and clinical analysis of spastic paraplegia 4.

Parkinsonism &amp; related disorders
2021

Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia - The SPASTOX Trial.

Movement disorders : official journal of the Movement Disorder Society
2020

Health service experiences among adults with hereditary spastic paraparesis or neurofibromatosis type 1.

Molecular genetics &amp; genomic medicine
2020

Complicated SPG4 presenting with recurrent urinary tract infection.

Journal of community hospital internal medicine perspectives
2020

KIF1A-related autosomal dominant spastic paraplegias (SPG30) in Russian families.

BMC neurology
2020

A novel phenotype of hereditary spastic paraplegia type 7 associated with a compound heterozygous mutation in paraplegin.

Muscle &amp; nerve
2019

Loss of paraplegin drives spasticity rather than ataxia in a cohort of 241 patients with SPG7.

Neurology
2017

An atypical case of SPG56/CYP2U1-related spastic paraplegia presenting with delayed myelination.

Journal of human genetics
2016

[X-linked hereditary spastic paraplegia due to mutation in the L1CAM gene: three cases reports of CRASH syndrome].

Revista de neurologia
Ver todos os 28 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Paraplegia espástica autossômica recessiva tipo 62.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Paraplegia espástica autossômica recessiva tipo 62

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Expanding the Phenotypic Spectrum of ERLIN1-Related SPG62: Report of Two Siblings With Behavioral Features and Hyperacusis.
    Clinical genetics· 2026· PMID 41251124mais citado
  2. ERLIN1: A central regulator of protein quality control, lipid homeostasis, and cellular signaling at the endoplasmic reticulum.
    Cellular signalling· 2026· PMID 41205880mais citado
  3. Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A&gt;C: A Case Report.
    The American journal of case reports· 2026· PMID 41496376mais citado
  4. KIF1C-related disorders: spastic ataxia or hypomyelinating leukodystrophy? A paradigm of classification ambiguity.
    Neurogenetics· 2025· PMID 40794111mais citado
  5. New variants and genotype-phenotype correlation in KIF5A mutation: the contribution of a large Italian cohort.
    Journal of medical genetics· 2025· PMID 40562529mais citado
  6. Six novel SACS mutations expand the autosomal recessive spastic ataxia of Charlevoix-Saguenay spectrum.
    Orphanet J Rare Dis· 2026· PMID 41923236recente
  7. Clinical, Radiological, and Genetic Profile of Patients with FA2H-Associated Neurodegeneration: Eight Cases from India and a Review of the Literature.
    Tremor Other Hyperkinet Mov (N Y)· 2026· PMID 41798181recente
  8. Peripheral Neuropathy-Predominant Adult-Onset Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: Novel Variant in the SACS gene.
    Ann Indian Acad Neurol· 2026· PMID 41784076recente
  9. The Cerebellar Cognitive-Affective Syndrome Scale Reveals Consistent, Early, and Progressive Neuropsychological Deficits in Autosomal-Recessive Spastic Ataxia of Charlevoix-Saguenay: A Large International Cross-Sectional Study.
    Mov Disord· 2026· PMID 41669957recente
  10. Generation of eight human induced pluripotent stem cells lines from patients with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).
    Stem Cell Res· 2026· PMID 41529449recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:401785(Orphanet)
  2. OMIM OMIM:615681(OMIM)
  3. MONDO:0014302(MONDO)
  4. GARD:17657(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q32143270(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Paraplegia espástica autossômica recessiva tipo 62
Compêndio · Raras BR

Paraplegia espástica autossômica recessiva tipo 62

ORPHA:401785 · MONDO:0014302
Prevalência
<1 / 1 000 000
Casos
7 casos conhecidos
Herança
Autosomal recessive
CID-10
G11.4 · Paraplegia espástica hereditária
CID-11
Início
Childhood, Infancy
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C4284588
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades